文献速递眼底病与葡萄膜炎神经眼科

GSK840通过抑制RIPK3/MLKL介导的视网膜神经节细胞坏死性凋亡减轻缺血/再灌注后的视网膜神经元损伤

GSK840 Alleviates Retinal Neuronal Injury by Inhibiting RIPK3/MLKL-Mediated RGC Necroptosis After Ischemia/Reperfusion.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

该研究在小鼠视网膜缺血/再灌注(IR)体内模型及原代小鼠视网膜神经节细胞(RGC)氧糖剥夺/复氧(OGDR)体外模型中,使用小分子化合物GSK840特异性抑制RIPK3/MLKL依赖性坏死性凋亡。结果显示GSK840可保留内层视网膜神经元(尤其RGC)、减少PI阳性RGC、改善IR所致视觉功能障碍,机制为抑制RIPK3/MLKL通路。

要点

  • 视网膜IR或OGDR后RGC中RIPK3/MLKL依赖性坏死性凋亡被快速激活。
  • GSK840保留内层视网膜神经元(尤其RGC)并维持内层视网膜结构与厚度。
  • GSK840改善IR所致视觉功能障碍并减少PI阳性RGC,机制为抑制RIPK3/MLKL通路。

核心结论

  • GSK840通过抑制RIPK3/MLKL介导的RGC坏死性凋亡,对IR后视网膜神经元损伤发挥保护作用。
  • GSK840可能成为缺血性视网膜病变中RGC变性的保护策略。

研究设计与样本

  • 建立小鼠视网膜IR体内模型及原代小鼠RGC的OGDR体外模型。
  • 使用小分子化合物GSK840特异性抑制RIPK3/MLKL依赖性坏死性凋亡。
  • 采用苏木精-伊红染色、光学相干断层扫描和视网膜电图评估视网膜结构与功能。
  • 采用碘化丙啶(PI)染色检测坏死性细胞死亡,采用蛋白质印迹分析和免疫荧光评估坏死性凋亡相关蛋白及内层视网膜神经元。

主要发现

  • 视网膜IR或OGDR后RGC中RIPK3/MLKL依赖性坏死性凋亡被快速激活。
  • GSK840通过保留内层视网膜神经元(尤其RGC)帮助维持相对正常的内层视网膜结构与厚度。
  • GSK840改善IR所致视觉功能障碍,表现为明视负反应、a波、b波和振荡电位的振幅改善。
  • GSK840治疗显著减少损伤后PI阳性RGC数量。
  • GSK840通过抑制RIPK3/MLKL通路减轻RGC坏死性凋亡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to explore the impact of GSK840 on retinal neuronal injury after retinal ischemia/reperfusion (IR) and its associated mechanism. METHODS: We established an in vivo mouse model of IR and an in vitro model of oxygen and glucose deprivation/reoxygenation (OGDR) in primary mouse retinal ganglion cells (RGCs). GSK840, a small-molecule compound, was used to specifically inhibit RIPK3/MLKL-dependent necroptosis. Retinal structure and function evaluation was performed by using hematoxylin and eosin staining, optical coherence tomography, and electroretinography. Propidium Iodide (PI) staining was used for detection of necroptotic cell death, whereas Western blot analysis and immunofluorescence were used to assess necroptosis-related proteins and inner retinal neurons. RESULTS: RIPK3/MLKL-dependent necroptosis was rapidly activated in RGCs following retinal IR or OGDR. GSK840 helped maintain relatively normal inner retinal structure and thickness by preserving inner retinal neurons, particularly RGCs. Meanwhile, GSK840 ameliorated IR-induced visual dysfunction, as evidenced by the improved amplitudes of photopic negative response, a-wave, b-wave, and oscillatory potentials. And GSK840 treatment significantly reduced the population of PI+ RGCs after injury. Mechanistically, GSK840 ameliorated RGC necroptosis by inhibiting the RIPK3/MLKL pathway. CONCLUSIONS: GSK840 exerts protective effects against retinal neuronal injury after IR by inhibiting RIPK3/MLKL-mediated RGC necroptosis. GSK840 may represent a protective strategy for RGC degeneration in ischemic retinopathy.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Feng Y, Hu C, Cui K, et al. GSK840 Alleviates Retinal Neuronal Injury by Inhibiting RIPK3/MLKL-Mediated RGC Necroptosis After Ischemia/Reperfusion. Invest Ophthalmol Vis Sci. 2023. PMID: 38015174. doi:10.1167/iovs.64.14.42

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。